Phase i study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 2140-2147

  Hochhauser, Daniel ^c,g   Meyer, Timothy ^c   Spanswick, Victoria J ^b   Wu, Jenny ^b   Clingen, Peter H ^b   Loadman, Paul ^d   Cobb, Margaret ^a   Gumbrell, Lindsey ^a   Begent, Richard H ^c   Hartley, John A ^b   Jodrell, Duncan ^e,f,g  

^a Cancer Research   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SJG 136; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA BINDING; DNA CROSS LINKING; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TUMOR CELL; VASCULAR LEAK SYNDROME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZODIAZEPINONES; DNA; HISTONES; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRROLES;

EID: 63449133609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1315     Document Type: Article

References (21)

1. Thurston DE. Advances in the study of pyrrolo[2,1- c] [1,4] benzodiazepine (PBD) antitumor antibiotics. In: Neidle S, Waring MJ, editors. Molecular aspects of anticancer drug-DNA interactions. London: The Mac-millan Press Ltd; 1993. pp. 54-88.
2. Gregson SJ, Howard PW, Hartley JA, et al. Design synthesis and evaluation of a novel pyrrolobenzodia- zepine DNA-interactive agent with highly efficient cross-linkingability and potent cytotoxicity. J Med Chem 2001;44:737-8.
3. Martin C, Ellis T, McGurk CJ, et al. Sequence- selective interaction of the minor-groove interstrand cross-linkingagent SJG-136 with naked and cellular DNA: footprintingand enzyme inhibition studies. Bio- chem 2005;44:4135-47.
4. Gregson SJ, Howard PW, JenkinsTC, et al. Synthesis of a novel C2/C'2-exo unsaturated pyrrolobenzodia- zepine cross-linkingagent with remarkable DNAbind- ingaffinity and cytotoxicity. Chem Communications 1999;9:797 -8.
5. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationallydesigned DNAminor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9.
6. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 2: Efficacy evaluations. Cancer Res 2004;64: 6700-6.
7. Simon R, Freidlin B, Rubinstein L,ArbuckSG, Collins J, Christian MC. Accelerated titration designsfor phase1 clinical trials in oncology. J National Cancer Inst1997; 89:1138-47.
8. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (comet) assay. In: Brown R, Boger-Brown U, editors. Methods in molecular medicine, vol. 28. Cyto- toxic drugresistance mechanisms. Humana Press; 1999. pp. 43 -154.
9. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumour and normal cells measured using the ''comet'' assay. Radiat Res1990;122:86-94.
10. Spanswick VJ, Craddock C, Sakhar M, et al. Repair of DNA interstrand crosslinks as a mechanism ofclin-ical resistance to melphalan in multiple myeloma. Blood 2002;100:224-9.
11. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-33.
12. Puvvada MS, Forrow SA, HartleyJA. Inhibition of bacteriophageT7RNA polymerase in vitro transcription by DNA-binding pyrrol [2,1 c][1,4]benzodiaze-pines. Biochem 1997;36:2478-84.
13. Thurston DE. Nucleic acid targeting: therapeutic strategies for the 21st century. Br J Cancer Res 1999; 80:65-85.
14. KarpJE, Ricklis RM, Balakrishnan K, et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007;110:1762 -9.
15. Rafi AQ,ZeytunA,Bradley MJ,et al. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunology 1998;161:3077 -86.
16. Assier E, JullienV, Lefort J, et al. NK cells and poly- morphonuclear neutrophils are both critical for IL-2 induced pulmonary vascular leak syndrome. J Immunology 2004;172:7661 -8.
17. Schnell R, Staak O, Borchmann P, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:1779 -86.
18. PazdurR,HoDH,DaughertyK,BradnerWT,Krakoe IH, Raber MN. Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest New Drugs 1991;9:337 -82.
19. Amlot PL, Stone MJ, Cunningham D, et al. APhaseI study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993;82:2624-33.
20. Al-Shaiba R, McMillan DC, Angerson WQJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory responsein patients with colorectal liver metastases. BrJ Cancer 2004;91:20-7.
21. Puzanov I, Lee W, Berlin JD, et al. Final results of phase I and pharmacokinetic trial ofSJG-136 administered on a daily ×3 schedule. J Clin Oncol 2008;26: abstr 2504.